Treg space continues to heat up as AbbVie puts up almost $50M upfront to partner with little-known biotech

AbbVie is joining its fellow Big Pharma competitors and jumping into the Treg space.

In a collaboration deal announced early Monday morning, the Chicago-based pharma company said it would be teaming up with private biotech Cugene to advance a single Treg program targeting IL-2. AbbVie is shelling out $48.5 million...

Click to view original post